SCI时时刷

search
+
Inevitable Progress--Relying on the Immune System, Not Chance
Inevitable Progress--Relying on the Immune System, Not Chance
Locoregional recurrence of head and neck cancer after curative therapy portends a poor prognosis even when resectable. Imm...
Using Circulating Tumor DNA for Colon Cancer Adjuvant Therapy: To Be or Not to Be?
Using Circulating Tumor DNA for Colon Cancer Adjuvant Therapy: To Be or Not to Be?
Thank you for sharing this Clinical Cancer Research article.NOTE: We request your email address only to inform the recip...
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma Elaine Chang, Ch...
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malign...
Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicent...
A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
AbstractPurpose: Selinexor is an oral selective inhibitor of exportin-1 (XPO1) with efficacy in various solid and hematolo...
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors
AbstractPurpose: The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile of mogamuli...
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
AbstractPurpose: Surgery often represents the best chance for disease control in locoregionally recurrent squamous cell ca...
Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
AbstractPurpose: Previously, clinical trials of experimental virotherapy for recurrent glioblastoma multiforme (GBM) demon...
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Ur...
A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Mela...
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
AbstractPurpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection m...
Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activatio...
Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Canc...
Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy
Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy
Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate...
Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen--Response
Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen--Response
Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpo...
18F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
18F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
AbstractPurpose: Hypoxia is a common characteristic of many tumor microenvironments, and it has been shown to promote supp...
Cholesterol-Lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity
Cholesterol-Lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity
Cholesterol-Lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity ...
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifi...
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Pat...
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
AbstractPurpose: The role of immunotherapy in hormone receptor (HR)-positive, HER2-negative breast cancer is underexplored...
T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Translational RelevanceOligodendrogliomas are intrinsic brain tumors that are incurable. In a screen for potential immunog...
Relevance of pRB Loss in Human Malignancies
Relevance of pRB Loss in Human Malignancies
AbstractThe retinoblastoma tumor suppressor protein (pRB) is a known regulator of cell-cycle control; however, recent stud...
Pathology: Hub and Integrator of Modern, Multidisciplinary [Precision] Oncology
Pathology: Hub and Integrator of Modern, Multidisciplinary [Precision] Oncology
Every profession has an essential, behind-the-scenes component without which it cannot function. Medicine is no exception....
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Brea...
A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma
A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma
AbstractPurpose: Ceritinib is an orally bioavailable, small-molecule inhibitor of anaplastic lympoma kinase (ALK), insulin...
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
AbstractPurpose: Soft-tissue sarcomas (STS) are a rare, heterogeneous group of mesenchymal tumors. For decades the mainsta...
Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome
Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome
Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome ...
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
AbstractPurpose: To assess the response to pexidartinib treatment in six cohorts of adult patients with advanced, incurabl...
Correction: KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms
Correction: KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms
In the original version of this article (1), the “Crizotinib” label in Fig. 4F is incorrect; the label should be “Selumeti...
阅读更多
format_indent_increase